GARFIELD-AF collects data on all components of the CHA2DS2-VASc and HAS-BLED risk stratification schemes to assess the risks of stroke and bleeding retrospectively.
Key Data:
- GARFIELD-AF has confirmed that CHA2DS2-VASc and HAS-BLED are both predictive of the risk of major outcomes (stroke/systemic embolism, major bleeding and mortality), and may provide value in guiding physicians in clinical decision-making
- Anticoagulation therapy, received by over 60% of patients in GARFIELD-AF cohorts 1 and 2, was associated with a substantially lower risk (35%) of all-cause death at 2-year follow-up
- The most common causes of death are not known to be significantly influenced by anticoagulation, which suggests that a more comprehensive approach to the management of AF may be needed to reduce the risk of death